Third Place at “TechGALA Grand Pitch 2026”
FerroptoCureFerroptoCure Co., Ltd. (Representative Director: Yuji Otsuki) won third place at “Grand Pitch 2026,” the main pitch event of the international technology event “TechGALA Japan 2026,” held in Nagoya, Aichi Prefecture, in January 2026.
TechGALA is an international technology event that brings together domestic and international startups, established companies, investors, and research institutions.
At “Grand Pitch,” startups selected from around the world present their innovative technologies and business visions, which are then evaluated based on criteria such as novelty, social impact, and business viability. The event is recognized as a platform for networking with innovators worldwide and for creating new business opportunities.
At the Grand Pitch, FerroptoCure was recognized not only for the novelty of its proprietary drug discovery technology but also for its new therapeutic approach to drug-resistant cancer and the potential for business expansion targeting the global market, earning third place among startups from around the world.
FerroptoCure will continue to advance the research and development of innovative cancer therapies targeting ferroptosis, while deepening collaborations with domestic and international companies and research institutions to bring these innovative treatments to market.
